Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies
Open accessThe DOI matches its Crossref record; 83 of the 90 references it cites were found in a registry or an index, and 3 are not checked yet; 73 of the 82 sources its claims cite were checked for support.
Abstract
Cetuximab and panitumumab are anti-EGFR monoclonal antibodies widely used for the treatment of colorectal cancers. However, due to various mechanisms of resistance to these targeted therapies, the patients’ responses vary. These resistances remain a major obstacle in treatment and overcoming them has become a key emphasis of current therapeutic strategies. Intrinsic and acquired resistance often lead to reactivation of downstream signaling pathways, mainly the RAS-RAF-MEK-ERK (MAPK pathway) and PI3K-AKT axes. Prior existing mutations in KRAS, NRAS, and BRAF result in primary resistance by constantly activating the signals, irrespective of EGFR inhibition. That said, acquired resistance manifests under therapeutic burden through the process of clonal evolution via KRAS and BRAF alterations, restoring MAPK pathway activity despite EGFR inhibition. In addition to those mutations, tumor cells exploit mechanisms independent of EGFR, such as the pathway bypass, which includes amplification of ERBB family receptors like HER2 (ERBB2) and activation of MET signaling. To overcome these resistances, novel strategies have emerged, which target multiple nodes within the oncogenic networks. Such methods include vertical pathway inhibition, multi-kinase inhibition, liquid-biopsy-guided therapy, and anti-EGFR rechallenge. Reactivation driven by secondary mutation can be prevented by targeting multiple nodes within the MAPK cascade simultaneously, which is referred to as the vertical pathway inhibition. Overall, this review underscores that overcoming therapeutic resistance requires a multidimensional approach that integrates molecular profiling, rational combination therapies, and adaptive treatment. Finally, these advances underscore the shift toward precision oncology, where therapy is tailored to tumor evolution, leading to improved response and patient outcome.
Verified 2026-11-19 · 3 references not checked yet
Overview
CoChat Summary
TL;DR
This review summarizes primary and acquired resistance mechanisms to cetuximab and panitumumab in metastatic colorectal cancer, emphasizing RAS/BRAF/PIK3CA alterations, bypass receptor signaling, and tumor microenvironment effects. It outlines emerging biomarker-guided combination strategies, including vertical pathway inhibition, HER2/MET blockade, and ctDNA/NGS monitoring.
Key findings
- RAS mutations account for approximately 40% of metastatic colorectal cancers and are established negative predictors of anti-EGFR response; expanded RAS mutations beyond KRAS exon 2 also predict resistance. BRAF V600E occurs in about 10–15% of CRCs, PIK3CA mutations in 15–20%, PTEN loss in 20–40% of mCRC, and HER2 amplification in 2–5% of all mCRC but up to 10–15% in RAS wild-type tumors.
- Acquired resistance develops within 12–18 months after initial response, driven by secondary KRAS mutations, EGFR ectodomain alterations such as S492R (cetuximab-resistant but panitumumab-sensitive), and clonal selection; bypass mechanisms include HER2/MET amplification, CAF-derived HGF/NRG1, EMT, hypoxia, and immunosuppressive microenvironment signaling.
- Combination strategies show clinical activity: BEACON CRC (encorafenib plus cetuximab improved overall survival), BREAKWATER (encorafenib, cetuximab, and mFOLFOX6 improved PFS and OS in first-line BRAF-mutant mCRC), CodeBreaK 300 (sotorasib plus panitumumab improved PFS in KRAS G12C), HER2-directed trials (HERACLES, MyPathway, DESTINY-CRC01, MOUNTAINEER), MET/EGFR inhibition (PERSPECTIVE), and ctDNA-guided rechallenge (CRICKET, CAVE).
- Liquid biopsy with ctDNA/NGS enables real-time detection of resistance mutations and negative hyperselection, but limitations include standardization, assay performance, cost, limited tumor shedding, and false negatives from low ctDNA shedding.
Methods
- Narrative review with a literature search conducted from 15 April to 20 May 2026 using PubMed, Scopus, Google Scholar, ResearchGate, and other sources; search terms covered cetuximab/panitumumab, colorectal cancer/metastatic colorectal cancer, resistance mechanisms, and combination therapy.
- PRISMA 2020 flow: 3326 records identified; after removing duplicates (n = 1244) and pre-2001/other records (n = 188), 1894 records were screened; 1810 were excluded, leaving 84 full-text records that met eligibility criteria.
- Inclusion criteria prioritized English-language peer-reviewed original research, clinical trials, experimental studies, reviews, and high-quality conference abstracts published between 2001 and May 2026 on mCRC treated with cetuximab or panitumumab, resistance mechanisms, and combination strategies; no primary data were collected.
Limitations
- The paper states that restricted institutional access to certain journals and databases may have limited retrieval of some full-text articles.
- The paper states that liquid biopsy/ctDNA approaches are limited by standardization, assay performance, economic feasibility, limited tumor shedding, restricted access to the bloodstream, and false negatives due to low shedding.
- Evident from the text: this is a narrative review without meta-analysis or quantitative synthesis, relying on published literature and potentially subject to selection or publication bias; the search was restricted to English-language records from 2001 to May 2026.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
47 Valid · 6 Not valid · 4 Not checked · 49 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who initially respond to anti-EGFR develop acquired resistance within 12 to 18 months due to secondary mutations in KRAS genes, EGFR exodomain alteration, and clonal selection [9].”
§ Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies > 1. Introduction
What the sources say
- Partly supportedcites [9] Misale, 2012, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature sourceExperimental — accuracy not yet measured
The paper reports that secondary resistance typically occurs within 9–18 months, not specifically 12–18 months, and identifies KRAS mutations and selection of pre-existing KRAS-mutant clones as resistance mechanisms (Abstract; page unavailable). It does not establish EGFR extracellular-domain alteration as a mechanism in its own study; that finding appears only in a cited reference. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BRAF mutation predicts resistance to EGRF antagonists, such as cetuximab and panitumumab, when used as monotherapy [17,21].”
§ Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies > 4. Mechanisms of Resistance to Anti-EGFR Therapy > 4.1. Primary Resistance
What the sources say
- Supportedcites [17] Zhao, 2017, Mechanisms of resistance to anti-EGFR therapy in colorectal cancer, Oncotarget source
The BRAF mutations section identifies BRAF V600E as a marker of resistance to anti-EGFR therapy in metastatic colorectal cancer. The table in Overcoming Resistance reports that BRAF mutation was associated with shorter survival after cetuximab or panitumumab treatment with or without chemotherapy, which includes monotherapy. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [21] Yaeger, 2012, BRAF mutations in colorectal cancer: Clinical relevance and role in targeted therapy, J. Natl. Compr. Cancer Netw. sourceExperimental — accuracy not yet measured
The ‘BRAF as a prognostic and predictive marker’ section reports that responses to cetuximab or panitumumab in BRAF-mutated colorectal cancer are extremely rare in the chemotherapy-refractory setting. It does not establish the claim specifically for EGFR-antagonist monotherapy across settings, and it reports two responses among 40 BRAF-mutated tumors. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It is involved in the regulation of cell differentiation, cell growth, and cell survival; as such, the BRAF mutation results in abnormal signaling pathways, leading to cell proliferation and inhibition of apoptosis by constitutively activating the MAPK pathway [17,23].”
§ Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies > 4. Mechanisms of Resistance to Anti-EGFR Therapy > 4.1. Primary Resistance
What the sources say
- Partly supportedcites [17] Zhao, 2017, Mechanisms of resistance to anti-EGFR therapy in colorectal cancer, Oncotarget sourceExperimental — accuracy not yet measured
The “BRAF mutations” section under primary resistance to anti-EGFR therapy states that BRAF V600E promotes tumor-cell proliferation and survival through constitutive MAPK activation. It does not specifically say that this inhibits apoptosis, and its statement concerns BRAF V600E rather than all BRAF mutations. The indexed passage has no page number. (LLM, conf=0.84)
- Partly supportedcites [23] Wang, 2024, Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations, Innovation sourceExperimental — accuracy not yet measured
The Introduction says BRAF mutations can persistently activate the MAPK pathway and cause uncontrolled cell proliferation. The 'Autophagy and apoptosis' section says this activation affects apoptosis, but does not establish that it inhibits apoptosis; the explicit inhibition statement appears only in the Abstract, which is excluded as evidence under the supplied rubric. Page numbers were not provided. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Mutations in KRAS exon 2 are common predictors of tumor resistance to EGFR antagonists [17].”
§ Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies > 4. Mechanisms of Resistance to Anti-EGFR Therapy > 4.1. Primary Resistance
What the sources say
- Supportedcites [17] Zhao, 2017, Mechanisms of resistance to anti-EGFR therapy in colorectal cancer, Oncotarget source
The ‘KRAS exon 2 mutations’ subsection under primary resistance explicitly calls these mutations the most common predictor of resistance to the anti-EGFR drugs cetuximab and panitumumab in patients with metastatic colorectal cancer. This directly supports the cited paraphrase in that clinical context. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Fortunately, the S492R mutation does not confer resistance to panitumumab [33,35,36,37].”
§ Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies > 4. Mechanisms of Resistance to Anti-EGFR Therapy > 4.2. Acquired Resistance
What the sources say
- Supportedcites [33] Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., and Shamseddine, A. (2026). EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance. Int. J. Mol. Sci., 27. source
Section 6.2.4 states that panitumumab retains activity against tumors harboring S492R, unlike cetuximab. Section 7.4 likewise says tumors with S492R may respond to panitumumab. (LLM, conf=0.92)
- Supportedcites [35] Sickmier, E.A., Kurzeja, R.J., Michelsen, K., Vazir, M., Yang, E., and Tasker, A.S. (2016). The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance. PLoS ONE, 11. source
The Introduction (page not supplied) states that EGFR S492R—called S468R in the mature-protein numbering used in this paper—confers resistance to cetuximab but remains responsive to panitumumab. The Results and Discussion also report that S468R blocks cetuximab binding but not panitumumab binding. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites [36] Esposito, 2013, The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies, Cancer Biol. Ther. source
- Supportedcites [37] Cruickshanks, 2014, When to screen and not to screen, Cancer Biol. Ther. source
The Abstract explicitly states that the EGFR S492R mutation conveys resistance to cetuximab but not to panitumumab. This directly supports the attributed claim. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
52 more claims · 18 with their cited sources checked
Create a free account to see all 106 claims and every source verdict.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 11
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 2×
“Patients who fail to respond to therapy initially exhibit intrinsic resistance, whereas those who relapse after initial response are associated with acquired resistance [9].”
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612 · cited 1×
“These adaptations allow tumor cells to survive under stress conditions and reduce their dependence on EGFR signaling [55].”
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · cited 1×
“EGFR is a prototypical transmembrane receptor tyrosine kinase (RTK) belonging to the ErbB family [8].”
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · cited 1×
“Clinical trials such as HERACLES [60], MyPathway [61], DESTINY-CRC01 [59], and MOUNTAINEER [62] have demonstrated significant clinical activity of HER2-targeted therapies in patients with HER2-positive, RAS-wild-type mCRC.”
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773 · cited 1×
“In addition to HGF and NRG1, CAFs secrete numerous cytokines and growth factors, including transforming growth factor β (TGF-β ), interleukin 6 (IL-6), and CXCL12, which collectively promote tumor survival and progression [50].”
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746 · cited 1×
“Such mechanisms include angiogenic escape and epithelial-to-mesenchymal transition (EMT) [25–27].”
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Cancer-associated fibroblasts: from basic science to anticancer therapy
Yang, D., Liu, J., Qian, H., & Zhuang, Q. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01013-0 · Cited by 572 · cited 1×
“Cancer-associated fibroblasts (CAFs) are one of the most abundant stromal cell populations in colorectal cancer and are increasingly recognized as key mediators of resistance to targeted therapies [49].”
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · cited 1×
“Beyond bypass loops, mutations in the extracellular domain of EGFR (EGFR-ECD mutation), such as the S492R mutation, can change the receptor shapes, which in turn prevents cetuximab binding [33,34].”
Yang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398 · cited 1×
“Interestingly, KRAS G12C (glycine to cysteine) can be targeted using the covalent inhibitors, such as sotorasib, in combination with EGFR antagonists, such as panitumumab [75].”
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319 · cited 10×
“Overall, these mutations represent as critical predictive biomarkers of intrinsic resistance to EGFR antagonists and cetuximab or panitumumab should be avoided in patients exhibiting such mutations [17].”
InfluentialWatanabe, J., Muro, K., Shitara, K., Yamazaki, K., Shiozawa, M., Ohori, H., Takashima, A., Yokota, M., Makiyama, A., Akazawa, N., et al. (2023) · JAMA · doi:10.1001/jama.2023.4428 · Cited by 280
Allegra, C. J., Rumble, R. B., Hamilton, S. R., Mangu, P. B., Roach, N., Hantel, A., & Schilsky, R. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9674 · Cited by 264 · cited 1×
“…guidelines from various organizations and societies, such as the European Society of Clinical Oncology (ESMO), American Society of Clinical Oncology (ASCO), and National Comprehensive Cancer Network, suggest routine testing for mutations in RAS and BRAF, highlighting their importance [28–32].”
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00150-x · Cited by 259 · cited 1×
“Clinical trials such as HERACLES [60], MyPathway [61], DESTINY-CRC01 [59], and MOUNTAINEER [62] have demonstrated significant clinical activity of HER2-targeted therapies in patients with HER2-positive, RAS-wild-type mCRC.”
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
Cheng, X. (2024) · doi:10.20944/preprints202406.0515.v1 · Cited by 257
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · cited 1×
“Such mechanisms include angiogenic escape and epithelial-to-mesenchymal transition (EMT) [25–27].”
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
Cheng, X. (2024) · Genes · doi:10.3390/genes15070903 · Cited by 243
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13665 · Cited by 214 · cited 1×
“Preexisting RAS mutations driving EGFR-independent signaling are seen in intrinsic resistance, whereas the emergence of secondary KRAS mutations or resistant subclonal populations’ expansion during treatment is observed in acquired resistance [13].”
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178 · cited 1×
“In response to such challenges, clinical trials, such as DESTINY-CRC01, HERACLES, MyPathway study, MOUNTAINEER, and TRIUMPH, explored targeted therapies against HER2 in mCRC [59–63 ,77– 79].”
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501912 · Cited by 166 · cited 1×
“Recently, the BREAKWATER trial demonstrated significant improvements in progression-free survival and overall survival after combining encorafenib and cetuximab with first-line chemotherapy, establishing a new treatment paradigm for patients with BRAF-mutant mCRC [57].”
BRAF Mutation in Colorectal Cancer: An Update: Supplementary Issue: Biomarkers for Colon Cancer
Barras, D. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s25248 · Cited by 138 · cited 1×
“BRAF is a serine/threonine protein kinase (signal transduction protein) and activating mutations in it accounts for around ten to fifteen percent of CRCs, mainly the BRAF V600E— a point mutation and a biomarker of poor prognosis [18,20–22].”
Allgayer, H., Mahapatra, S., Mishra, B., Swain, B., Saha, S., Khanra, S., Kumari, K., Panda, V. K., Malhotra, D., Patil, N. S., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02338-2 · Cited by 127
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123 · cited 2×
“BRAF is a serine/threonine protein kinase (signal transduction protein) and activating mutations in it accounts for around ten to fifteen percent of CRCs, mainly the BRAF V600E— a point mutation and a biomarker of poor prognosis [18,20–22].”
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121 · cited 2×
“This process recruits and activates AKT, which subsequently regulates multiple downstream effectors involved in cell survival, growth, and resistance to apoptosis [44,45].”
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119 · cited 1×
“Despite strong preclinical evidence, clinical targeting of IGF-1R requires more clinical evidence to support its therapeutic application [39].”
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Temraz, S., Mukherji, D., & Shamseddine, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922976 · Cited by 117 · cited 2×
“In contrast to the MAPK pathway, the PI3K/AKT pathway primarily regulates cell survival, metabolism, growth, and drug resistance [10,11].”
Cremolini, C., Chalabi, M., Élez, E., Fassan, M., Gelli, M., Goèré, D., Modest, D. P., Viladot, C. M., Osterlund, P. J., Ricke, J., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.03.005 · Cited by 108
Ghoreyshi, N., Heidari, R., Farhadi, A., Chamanara, M., Farahani, N., Vahidi, M., & Behroozi, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-01816-9 · Cited by 91 · cited 1×
“Modern NGS platforms and highly sensitive liquid biopsy assays can detect mutations at substantially lower frequencies, improving identification of clinically relevant resistant clones [16].”
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., Fischer von Weikersthal, L., Caca, K., Kretzschmar, A., Goekkurt, E., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01332 · Cited by 86
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82 · cited 2×
“They cycle between active state (GTP bound) and inactive state (GDP bound) and work as downstream effectors within the mitogen-activated protein kinase (MAPK) pathway [12].”
Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Van Cutsem, E., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03235-9 · Cited by 82
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82 · cited 3×
“BRAF is a serine/threonine protein kinase (signal transduction protein) and activating mutations in it accounts for around ten to fifteen percent of CRCs, mainly the BRAF V600E— a point mutation and a biomarker of poor prognosis [18,20–22].”
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
Sickmier, E. A., Kurzeja, R. J. M., Michelsen, K., Vazir, M., Yang, E., & Tasker, A. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163366 · Cited by 76 · cited 1×
“Fortunately, the S492R mutation does not confer resistance to panitumumab [33,35–37].”
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61 · cited 1×
“The dynamic nature of these resistance mechanisms, mainly the MET amplification and ECD mutations during treatment, highlights the clinical utility of longitudinal ctDNA monitoring to iden-https tify molecular relapses [33,38].”
Siena, S., Di Bartolomeo, M., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4000 · Cited by 54
Esposito, C., Rachiglio, A. M., La Porta, M. L., Sacco, A., Roma, C., Iannaccone, A., Tatangelo, F., Forgione, L., Pasquale, R., Barbaro, A., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26340 · Cited by 53 · cited 1×
“This mutation confers resistance to cetuximab but retains sensitivity to panitumumab due to distinct epitope binding [33,36].”
Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy
Han, B., Lin, X., & Hu, H. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-29 · Cited by 53 · cited 2×
“This process recruits and activates AKT, which subsequently regulates multiple downstream effectors involved in cell survival, growth, and resistance to apoptosis [44,45].”
Pietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02026 · Cited by 51 · cited 2×
“The phase III CodeBreaK 300 trial demonstrated improved progression-free survival with the combination of sotorasib and panitumumab compared with standard treatment, supporting the concept of vertical pathway inhibition in KRAS G12C-mutated tumors [58].”
Next-generation sequencing methodologies to detect low-frequency mutations: “Catch me if you can”
Menon, V., & Brash, D. E. (2023) · Mutation Research - Reviews in Mutation Research · doi:10.1016/j.mrrev.2023.108471 · Cited by 48 · cited 1×
“The detection of low-frequency RAS-mutant subclones remains analytically challenging, as conventional sequencing approaches may fail to identify variants present at low variant allele frequencies (VAFs) [15].”
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers · doi:10.3390/cancers13051031 · Cited by 43 · cited 1×
“The combination of bevacizumab (anti-angiogenic agents) and EGFR inhibitors has been explored as a strategy to improve the therapeutic outcome [81,82].”
Thibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J. (2023) · Cancers · doi:10.3390/cancers15030784 · Cited by 40 · cited 2×
“Although the PI3K family comprises three classes, resistance to anti-EGFR therapy is primarily associated with aberrant activation of Class I PI3Ks and downstream AKT/mTOR signaling [40–45].”
Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39 · cited 3×
“…murine sarcoma viral oncogene homolog B1; ERK—extracellular signal-regulated kinase; MEK—mitogen-activated protein kinase kinase; EGFR-ECD—epidermal growth factor receptor extracellular domain; HER2—human epidermal growth factor receptor 2; MET—mesenchymal-to-epithelial transition factor.”
Napolitano, S., Martini, G., Ciardiello, D., Di Maio, M., Normanno, N., Avallone, A., Martinelli, E., Maiello, E., Troiani, T., & Ciardiello, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.940523 · Cited by 35 · cited 1×
“Studies such as CRICKET and CAVE have demonstrated that patients with elimination of resistant RAS and EGFR mutant clones can regain sensitivity to cetuximab-based therapy, reinforcing the need to integrate molecular monitoring into clinical decision-making [68,69].”
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32 · cited 10×
“The ERK then translocates into the nucleus, where it activates MYC and FOS (transcription factors), ultimately driving the cell cycle forward [10,11].”
InfluentialClass II phosphatidylinositol 3-kinase isoforms in vesicular trafficking
Yoshioka, K. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200835 · Cited by 31
Siena, S., Raghav, K., Masuishi, T., Yamaguchi, K., Nishina, T., Elez, E., Rodriguez, J., Chau, I., Di Bartolomeo, M., Kawakami, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53223-3 · Cited by 30 · cited 2×
“Clinical trials such as HERACLES [60], MyPathway [61], DESTINY-CRC01 [59], and MOUNTAINEER [62] have demonstrated significant clinical activity of HER2-targeted therapies in patients with HER2-positive, RAS-wild-type mCRC.”
Zhang, W., Jin, C., Liu, S., Wan, X., Li, Y., Liu, J., Duan, Z., Ma, J., & Gao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757513 · Cited by 22 · cited 1×
“Tumor-associated macrophages (TAMs) [52], regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs) create an immunosuppressive environment that promotes tumor progression and limits the antitumor immune response [53].”
Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
Yoshikawa, A., & Nakamura, Y. (2022) · Cancers · doi:10.3390/cancers15010183 · Cited by 21 · cited 1×
“In response to such challenges, clinical trials, such as DESTINY-CRC01, HERACLES, MyPathway study, MOUNTAINEER, and TRIUMPH, explored targeted therapies against HER2 in mCRC [59–63 ,77– 79].”
BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy
Yaeger, R., & Saltz, L. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0148 · Cited by 18 · cited 1×
“The BRAF mutation predicts resistance to EGRF antagonists, such as cetuximab and panitumumab, when used as monotherapy [17,21].”
Lièvre, A., Ouine, B., Canet, J., Cartier, A., Amar, Y., Cacheux, W., Mariani, O., Guimbaud, R., Selves, J., Lecomte, T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.353 · Cited by 18 · cited 1×
“Amplification of RTKs, such as HER2 and MET, are well-known mechanisms of resistance in mCRC [76].”
The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology
Rouvinov, K., Naamneh, R., Yakobson, A., Najjar, W., Abu Amna, M., Soklakova, A., Abu Zeid, E. E. D., Brenner, R., Asla, M., Ghalion, F. A., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16040523 · Cited by 14 · cited 3×
“Analytes, such as the ctDNA, extracellular vesicles (EVs), cell-free RNAs (cfRNAs), circulating tumor cells (CTCs), tumor-associated microRNAs, and tumor-educated platelets, can be assessed using liquid biopsy [83].”
InfluentialExpert consensus on the diagnosis and treatment of solid tumors with BRAF mutations
Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100661 · Cited by 14
Imai, M., Nakamura, Y., Shin, S., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00385 · Cited by 13 · cited 1×
“In response to such challenges, clinical trials, such as DESTINY-CRC01, HERACLES, MyPathway study, MOUNTAINEER, and TRIUMPH, explored targeted therapies against HER2 in mCRC [59–63 ,77– 79].”
Desai, O., Rathore, M. G., Boutros, C. S., Wright, M., Bryson, E., Curry, K., & Wang, R. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101354 · Cited by 12 · cited 1×
“Human epidermal growth factor receptor 2 (HER2/ERBB2) possesses potent kinase activity but lacks a known ligand, whereas HER3 has a ligand binding site but lacks a strong kinase activity [33,46].”
Raimondi, A., Randon, G., Prisciandaro, M., Pagani, F., Lonardi, S., Antoniotti, C., Bozzarelli, S., Bianchi, A. S., Tampellini, M., Fanchini, L., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34156 · Cited by 11
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11 · cited 1×
“As tumors grow beyond the reach of blood vessels, hypoxia leads to the stabilization of hypoxia-inducible factor 1 α (HIF-1 α ), which then induces the expression of vascular endothelial growth factor (VEGF) and promotes angiogenesis [54].”
Tu, J., Zheng, L., Yan, L., Shi, L., & Kuang, Z. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01465-3 · Cited by 11 · cited 1×
“Colorectal cancers (CRCs) are the third most common malignancy and the second leading cause of cancer death worldwide, with the highest incidence in areas including East Asia, North America, and Europe [1,2].”
Vaghi, C., Tosi, F., Mauri, G., Bonazzina, E., Amatu, A., Bencardino, K., Piscazzi, D., Roazzi, L., Villa, F., Maggi, M., et al. (2026) · Drugs · doi:10.1007/s40265-025-02253-2 · Cited by 11
KRAS, a New Target for Precision Medicine in Colorectal Cancer?
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Delaye, M., Camilleri, G. M., Tarabay, A., Valéry, M., Fuerea, A., Pudlarz, T., et al. (2024) · Cancers · doi:10.3390/cancers16203455 · Cited by 11
Update on Anti-Angiogenesis Therapy in Colorectal Cancer
Ciombor, K. K., & Goldberg, R. M. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0292-3 · Cited by 11
Lim, A. R., Kim, B., Kim, J. H., Hyun, M. H., Park, K. H., Kim, Y. H., & Lee, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1390452 · Cited by 10 · cited 1×
“A combination of alpelisib (oral selective inhibitor of class I PI3K p110 α ) and capecitabine, an oral prodrug of 5-FU (fluorouracil), in a Phase Ib trial showed that in PIK3CA mutant CRC, the combination therapy was tolerable and showed antitumor activity [71].”
Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10
Flegiel, E., Piotrowska, M., Ptasznik, M., Baran, A., Lenart, J., Podrażka, M., Mazurek, J., Stachowicz, H., Bartos, W., & Adamczyk, M. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.229 · Cited by 8 · cited 1×
“With advances in genomic profiling, liquid biopsy has greatly improved the identification of resistance drivers and contributed to development of novel combination strategies that target multiple pathways simultaneously [4,5].”
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
Mo, C., Sterpi, M., Jeon, H., & Bteich, F. (2024) · Cancers · doi:10.3390/cancers16162854 · Cited by 8 · cited 1×
“In HER2-amplified tumors, coexisting PIK3CA mutations may reduce the efficacy of HER2-targeted therapies, such as trastuzumab, by maintaining downstream PI3K/AKT signaling despite receptor inhibition [48].”
Ur Rahman, M., Hussain, H. R., Akram, H., Gulzar, F., Nouman, M., Farooq, H., Ashfaq, A., & Kalsoom, Z. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.344 · Cited by 6
Fukuda, K., Osumi, H., Yoshinami, Y., Ooki, A., Takashima, A., Wakatsuki, T., Hirano, H., Nakayama, I., Ouchi, K., Sawada, R., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05893-1 · Cited by 5 · cited 1×
“Studies such as CRICKET and CAVE have demonstrated that patients with elimination of resistant RAS and EGFR mutant clones can regain sensitivity to cetuximab-based therapy, reinforcing the need to integrate molecular monitoring into clinical decision-making [68,69].”
Tabernero, J., Van Cutsem, E., Prausová, J., Isambert, N., Neuzillet, C., Siena, S., Pietrantonio, F., Falk, S., Wainberg, Z. A., Raghav, K. P. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.tps149 · Cited by 4
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4 · cited 9×
“Studies such as CRICKET and CAVE showed that restarting the same therapy in carefully selected patients can lead to increased overall survival and ORR [33].”
InfluentialPopescu, I., Croitoru, V. M., Croitoru-Cazacu, I. M., Dudau, A.-M., Herlea, V., Dima, S. O., & Croitoru, A. E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070750 · Cited by 4 · cited 1×
“…RAS mutations, which can be missed by conventional sequencing, can also lead to intrinsic resistance, necessitating the need for highly sensitive methods like next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis to detect mutations and guide treatment strategies [14].”
Bekaii‐Saab, T., Cutsem, E. V., Cubillo, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps3616 · Cited by 4
Dankner, M., Dubé, L.-R., Sorin, M., Stein, A. J. B., Nowakowski, A., Park, C. L., Magrill, J., Lazaratos, A.-M., Romero, J. M., Batist, G., et al. (2025) · Current Oncology · doi:10.3390/curroncol32110624 · Cited by 3
VPS34 in Autophagy, Cancer and Cancer Therapy
Bartolini, E., Janji, B., & Gao, R. (2026) · doi:10.20944/preprints202603.0323.v1 · Cited by 1
De, S. K. (2023) · Medicines for Cancer · doi:10.1016/b978-0-443-13312-1.00009-x · Cited by 1
Aspirin use and PI3K mutations in metastatic colorectal cancer (mCRC).
Payapwattanawong, S., Osterlund, E., Vetere, G., Bent, A. H., Dasari, A., Kee, B. K., Parseghian, C., Willis, J., Shen, J. P. Y. C., Raghav, K. P. S., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco.2026.44.2_suppl.189 · Cited by 1 · cited 2×
“PIK3CA-associated adverseprognosiswas notobservedamong aspirinusers,although nosignificantinteraction wasdetected [72] Abbreviations: ctDNA—circulating tumor DNA; EGFR—epidermal growth factor receptor; HER2—human epidermal growth factor receptor 2; IHC—immunohistochemistry; ISH—in situ…”
When to screen and not to screen
Cruickshanks, N. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.27741 · Cited by 1 · cited 1×
“Fortunately, the S492R mutation does not confer resistance to panitumumab [33,35–37].”
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00005-2 · Cited by 1
Zauderer, M. G., Traina, T. A., & Lichtman, S. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1398-5.10010-4
Pratt, V.M., Scott, S.A., Pirmohamed, M., Esquivel, B., Kattman, B.L., and Malheiro, A.J. (2012). Cetuximab Therapy and RAS and BRAF Genotype. MINI Medical Genetics Summaries [Internet], National Center for Biotechnology Information.
(n.d.)
UnresolvedNaeim, A., Reuben, D.B., and Ganz, P.A. (2012). Novel and targeted therapies. Management of Cancer in the Older Patient, W.B. Saunders.
(n.d.)
UnresolvedBRAF Mutation in Colorectal Cancer: An Update
Barras (2015) · Biomark. Cancer
UnresolvedExpert consensus on the diagnosis and treatment of solid tumors with BRAF mutations
Wang (2024) · Innovation
UnresolvedOncology, Pro (2026, June 20). BRAF in Colorectal Cancer: ESMO Biomarker Factsheet. Available online: https://oncologypro.esmo.org/publications/esmo-factsheets-on-biomarkers/braf-in-colorectal-cancer.
(n.d.)
Unresolved(2026, June 05). European Medical Journal Phase III Data Examines New Regimen in BRAF-Mutant Colorectal Cancer: ASCO 2025. Available online: https://www.emjreviews.com/oncology/news/phase-iii-data-examines-new-regimen-in-braf-mutant-colorectal-cancer-asco-2025.
(n.d.)
Unresolved(2026, April 15). BREAKWATER: Analysis of First-Line Encorafenib + Cetuximab + Chemotherapy in BRAF V600E-Mutant Metastatic Colorectal Cancer. ASCO, Available online: https://www.asco.org/abstracts-presentations/241160.
(n.d.)
Unresolved
Cited by
Porphyrin-Based Compounds in Medicine: From Photodynamic Therapy to Theranostics
Rodzoń-Wańczura, U., Aebisher, D., Ramesh, T. S., Dynarowicz, K., Filip, M., & Bartusik‐Aebisher, D. (2026) · Molecules · doi:10.3390/molecules31193488
Self-citation
Metadata
- Authors
- Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D.
- Affiliations
- Medical University of Lodz (PL)
- Department of Biochemistry and General Chemistry, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland
- University of Rzeszów (PL)
- Corresponding author
- Henrykowska, Gabriela
- Aebisher, David
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2026-07-03
- Volume
- 19
- Issue
- 7
- Pages
- 1041
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC13415011
- OpenAlex
- W7167210935
- Cited by
- 1
- References
- 84
- Citations by year
- 2026: 1
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- cetuximab, panitumumab, anti-EGFR therapy resistance, colorectal cancer, KRAS mutation, BRAF mutation, RAS/MAPK pathway, PI3K/Akt signaling, clonal evolution, HER2 amplification, C-MET signaling, multikinase inhibitor, liquid biopsy, combination therapy, precision oncology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.